Holen Sie sich die Stockscreener-App
56.36
0.42%
-1.00
Schlusskurs vom Vortag:
$57.36
Offen:
$57
24-Stunden-Volumen:
1.52M
Relative Volume:
0.61
Marktkapitalisierung:
$5.42B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-20.13
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+10.74%
1M Leistung:
+3.62%
6M Leistung:
+35.70%
1J Leistung:
+14.60%
1-Tages-Spanne:
$55.65
$58.00
1-Wochen-Bereich:
$51.16
$59.77
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.91 | 5.47B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.06 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.57 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.91 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Guggenheim Capital LLC Sells 37,778 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG Stock Analysis and ForecastMarket Sentiment Indicators & High Profit Market Ideas - earlytimes.in
CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
(CRSP) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Jump Financial LLC Buys New Shares in CRISPR Therapeutics AG $CRSP - MarketBeat
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
State Board of Administration of Florida Retirement System Acquires New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG: Stock surge amid challenges - MSN
Crispr Therapeutics AG: Stock Surge Amid Challenges - TipRanks
Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
50,250 Shares in CRISPR Therapeutics AG $CRSP Purchased by Philadelphia Trust Co. - MarketBeat
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown - MSN
Will CRISPR Therapeutics AG (1CG) stock return to pre crash levelsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser
Is CRISPR Therapeutics AG stock a bargain at current levelsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Cathie Wood’s Buys And Rumors Aside, Here’s Why Crispr Therapeutics Is A Strong Buy (CRSP) - Seeking Alpha
Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Nasdaq Index Biotech Momentum - Kalkine Media
Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Will CRISPR Therapeutics AG stock continue upward momentumLayoff News & Weekly Top Stock Performers List - Newser
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stockJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform benchmarksMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform value peers2025 Price Targets & High Accuracy Trade Alerts - Newser
Will CRISPR Therapeutics AG (1CG) stock hit analyst forecastsMarket Sentiment Summary & AI Based Trade Execution Alerts - Newser
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - MSN
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha
The Best CRISPR Companies for 2025 - The Motley Fool
Crispr Therapeutics (CRSP) Gains Amid Takeover Speculation - GuruFocus
Crispr Therapeutics pares loss amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha
Inflation Data: Can SGBX stock maintain operating marginsMarket Performance Recap & Detailed Earnings Play Alerts - BỘ NỘI VỤ
Crispr Therapeutics (CRSP) Shares React to M&A Rumor - GuruFocus
Crispr Therapeutics rumor highlighted in Betaville blog - TipRanks
Loomis Sayles & Co. L P Has $41.68 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - MSN
West Family Investments Inc. Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Sold by Cetera Investment Advisers - MarketBeat
Ameritas Investment Partners Inc. Purchases Shares of 8,451 CRISPR Therapeutics AG $CRSP - MarketBeat
Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy - Insider Monkey
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility - Yahoo Finance
Why CRISPR Therapeutics AG (1CG) stock could be next leaderWeekly Investment Summary & Technical Buy Zone Confirmation - BỘ NỘI VỤ
Why CRISPR Therapeutics (CRSP) Is Up 6.1% After Positive CTX310 Trial and Earnings Beat - Sahm
CRSP Price History for Crispr Therapeutics Ag Stock - Barchart.com
Price-Driven Insight from (CRSP) for Rule-Based Strategy - news.stocktradersdaily.com
CRISPR Therapeutics (CRSP): Exploring Valuation After Analyst Upgrades and Q3 Clinical Progress - Sahm
Himension Capital Singapore PTE. LTD. Sells 10,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Magnetar Financial LLC Invests $319,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Chardan Capital Lowers Price Target for CRSP Despite Buy Rating - GuruFocus
Chardan Cuts Price Target on CRISPR Therapeutics to $74 From $82, Keeps Buy Rating - MarketScreener
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):